SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Petrov et al. (2016), Adv Ther. 33: 96–115.
Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Brzheskiy et al. (2015), Adv Ther. 32: 1263–1279.
The mitochondria-targeted antioxidant SkQ1 restores αB-crystallin expression and protects against AMD-like retinopathy in OXYS rats.
Muraleva et al. (2014), Cell Cycle. 13(22): 3499–3505.
SkQ1 slows development of age-dependent destructive processes in retina and vascular layer of eyes of wistar and OXYS rats.
Saprunova et al. (2012), Biochemistry (Mosc), 77:648-58
Therapeutic action of the mitochondria-targeted antioxidant SkQ1 on retinopathy in OXYS rats linked with improvement of VEGF and PEDF gene expression.
Markovets et al. (2011), PLoS One. 6:e21682.
Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals.
Neroev et al. (2008), Biochemistry (Mosc), 73:1317-28.
View All News
View All Publications